BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 15262695)

  • 1. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.
    Maurer T; Poncelet A; Berger T
    Arch Dermatol; 2004 Jul; 140(7):845-9. PubMed ID: 15262695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prurigo nodularis of Hyde treated with low-dose thalidomide.
    Orlando A; Renna S; Cottone M
    Eur Rev Med Pharmacol Sci; 2009; 13(2):141-5. PubMed ID: 19499850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide in 42 patients with prurigo nodularis Hyde.
    Andersen TP; Fogh K
    Dermatology; 2011; 223(2):107-12. PubMed ID: 21952556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thalidomide treatment of prurigo nodularis].
    Jøhnke H; Zachariae H
    Ugeskr Laeger; 1993 Sep; 155(38):3028-30. PubMed ID: 8256312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
    Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GR
    Am J Med; 2005 Mar; 118(3):246-50. PubMed ID: 15745722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of lenalidomide in treating refractory prurigo nodularis.
    Liu H; Gaspari AA; Schleichert R
    J Drugs Dermatol; 2013 Mar; 12(3):360-1. PubMed ID: 23545923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral neuropathy associated with nodular prurigo.
    Bharati A; Wilson NJ
    Clin Exp Dermatol; 2007 Jan; 32(1):67-70. PubMed ID: 17034423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of prurigo nodularis with topical capsaicin.
    Ständer S; Luger T; Metze D
    J Am Acad Dermatol; 2001 Mar; 44(3):471-8. PubMed ID: 11209117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy.
    Kocer B; Sucak G; Kuruoglu R; Aki Z; Haznedar R; Erdogmus NI
    Acta Neurol Belg; 2009 Jun; 109(2):120-6. PubMed ID: 19681443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis.
    Sardana K; Gupta A; Sinha S
    Clin Exp Dermatol; 2020 Jan; 45(1):92-96. PubMed ID: 31132160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide neuropathy: an electrophysiologic study.
    Lagueny A; Rommel A; Vignolly B; Taieb A; Vendeaud-Busquet M; Doutre MS; Julien J
    Muscle Nerve; 1986; 9(9):837-44. PubMed ID: 3023998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis.
    Ferrándiz C; Carrascosa JM; Just M; Bielsa I; Ribera M
    Dermatology; 1997; 195(4):359-61. PubMed ID: 9529557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case series of 48 patients treated with thalidomide.
    Doherty SD; Hsu S
    J Drugs Dermatol; 2008 Aug; 7(8):769-73. PubMed ID: 18720694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
    Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
    J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide.
    Lan CC; Lin CL; Wu CS; Chai CY; Chen WT; Chen GS
    J Dermatol; 2007 Apr; 34(4):237-42. PubMed ID: 17352720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of tracrolimus 0.1% ointment in prurigo].
    Lee HH; Sterry W; Worm M
    J Dtsch Dermatol Ges; 2005 Sep; 3(9):690-4. PubMed ID: 16173976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers.
    Jacobson JM; Greenspan JS; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Pulvirenti JJ; Hooton TM; Shikuma C
    J Infect Dis; 2001 Jan; 183(2):343-346. PubMed ID: 11120935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
    Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
    Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide for the treatment of chronic refractory prurigo nodularis.
    Aguh C; Kwatra SG; He A; Okoye GA
    Dermatol Online J; 2018 Mar; 24(3):. PubMed ID: 29634881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.